智通财经APP获悉，沛嘉医疗-B(09996)午前涨近3%，截至发稿，涨2.25%，报4.09港元，成交额613.75万港元。
消息面上，沛嘉医疗-B发布截至2024年12月31日止年度营运数据，收入约人民币6.1亿元-6.3亿元，同比增长约38.3%-42.8%。
公告称，强劲的收入增长主要归功于：集团所有神经介入产品线的持续快速增长；及集团在中国经导管主动脉瓣置换(TAVR)市场的份额扩大。于报告期间，由于手术渗透率的提高、集团在带量采购中中标，以及其全面的产品管线及有效的营销策略，出血类、缺血类及通路类神经介入产品线均实现显著的收入增长。
主要驱动因素包括：DCwire®微导丝在全国范围内的首年成功推出，得到了用户的积极反馈和市场的广泛采用；集团的现有优势产品Syphonet®取栓支架及Fastunnel®输送型球囊扩张导管凭借差异化产品设计及创新手术技术进一步渗透市场；及凭借可靠的产品质量及品牌知名度，集团的弹簧圈产品在带量采购中获持续采用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.